ABSTRACT
The United Nations Programme on Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) estimates that in 2014 more than 36.9 million people lived with HIV-1. Various classical strategies and other novel methodologies such as neutralizing antibodies or dendritic cell (DC)-based immunotherapies are being researched as therapeutic HIV vaccine candidates. In HIV-1 vaccination, various approaches such as HIV-derived peptides, viral proteins, DNA, RNA, or inactivate viral particles have been used to improve antigen loading in DCs and to enhance immune responses. The most successful results in HIV DC-based clinical trials have been those using complete inactivated viruses. Several key aspects of DC-based therapies should be meticulously analyzed in therapeutic vaccines development. It includes the election of target antigen, viral inactivation method, the DCs isolation procedure or the vaccination strategy, antigen doses, routes of administration, and so on.
